SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics. CA Cancer J Clin. 2007; 57: 4366.
  • 2
    The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2007. Available at: http://ganjoho.ncc.go.jp/public/statistics/backnumber/2007_en.html Accessed on February 28, 2008
  • 3
    Sener SF,Fremgen A,Menck HR,Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999; 189: 17.
  • 4
    Imamura M,Doi R,Imaizumi T, et al. A randomized multicenter trial comparing resection and radiochemotherapy for respectable locally invasive pancreatic cancer. Surgery. 2004; 136: 10031011.
  • 5
    Japan Pancreas Society. Pancreatic cancer registry report 2007. Suizo. 2007; 22: 39.
  • 6
    Pedrazzoli S,DiCarlo V,Dionig R, et al.and the Lymphadenectomy Study Group. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. A multicenter, prospective randomized study. Ann Surg. 1998; 228: 508517.
  • 7
    Yeo CY,Cameron JL,Lillemoe KD, et al. Pancreaticoduodenectomy with or eithout distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2. Ann Surg. 2002; 236: 355368.
  • 8
    Farnell MB,Pearson RK,Sarr MG, et al. and the Pancreas Cancer Working Group. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in respectable pancreatic head adenocarcinoma. Surgery. 2005; 138: 618630.
  • 9
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998; 352: 930942.
  • 10
    NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 14441450.
  • 11
    Sakuramoto S,Sasako M,Yamaguchi T, et al.ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357: 18101820.
  • 12
    Kalser MH,Ellenberg SS. Pancretic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120: 899903.
  • 13
    Bakkevold K,Arnesjo B,Dahl O,Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of cater-results of a controlled, prospective randomized multicenter study. Eur J Can. 1993; 29A: 698703.
  • 14
    Study Group of Surgical Adjuvant Therapy for Carcinoma of the Pancreas, Biliary Tract, Takada T,Amano H,Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95: 16851695.
  • 15
    Kosuge T,Kiuchi T,Mukai K,Kakizoe T for the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006; 36: 159165.
  • 16
    Klinkenbijl JHG,Jeekel J,Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC GITCCG. Ann Surg. 1999; 230: 776784.
  • 17
    Neoptolemos JP,Stocken DD,Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 12001210.
  • 18
    Stocken DD,Buchler MW,Dervenis C, et al on behalf of the Pancreatic Cancer Meta-analysis Group. Meta-analysis of randomized adjuvant trials for pancreatic cancer. Br J Cancer. 2005; 92: 13721381.
  • 19
    Burris HAIII,Moore MJ,Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 24032413.
  • 20
    Oettle H,Post S,Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA. 2007; 297: 267277.
  • 21
    Fujii S,Kitano S,Irenaka K,Shirasak T. Effect of coadministration of uracil or cytosine on the anti-tumour activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann. 1979; 70: 209214.
  • 22
    Rauchwerger DR,Firby PS,Hedley DW,Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000; 60: 60756079.
  • 23
    Seto Y,Yoh K,Asoh H,Yamamoto H,Semba H,Ishinose Y. A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer. Br J Cancer. 2002; 86: 17011704.
  • 24
    Ichinose Y,Seto T,Semba H, et al. UFT plus gemcitabine combination chemotherapy in patients with advanced nonsmall cell lung cancer: a multi-institutional phase II trial. Br J Cancer. 2005; 93: 770773.
  • 25
    Herrmann R,Bodoky G,Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007; 25: 22122217.
  • 26
    Japan Pancreatic Society. Classification of Pancreatic Carcinoma. 2nd ed. Tokyo, Japan: Kanehara & Co. Ltd.; 2003.
  • 27
    Neoptoleomos JP,Dunn JA,Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet. 2001; 358: 15761585.
  • 28
    Feliu J,Mel R,Borrega P, et al. on behalf of the Oncopaz cooperative group, Spain. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol. 2002; 13: 17561762.
  • 29
    Lee J,Park JO,Kim WS, et al. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Oncology. 2004; 66: 3237.
  • 30
    Onoue M,Terada T,Okuda M, et al. Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer. Int J Clin Oncol. 2004; 9: 174178.
  • 31
    Neoptolemos JP,Stocken DD,Dunn JA, et al. European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001; 234: 758768.
  • 32
    Lim JE,Chien MW,Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma. A population-based, linked database analysis of 396 patients. Ann Surg. 2003; 237: 7485.
  • 33
    Berger AC,Watson JC,Ross EA,Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2004; 70: 235240.